QCG
FDMT icon

Quadrant Capital Group’s 4D Molecular Therapeutics FDMT Stock Holding History

Quadrant Capital Group’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-95
Closed -$885 – 1691
2026
Q1 		$885 Hold
95
– – ﹤0.01% 2598
2025
Q4 		$713 Hold
95
– – ﹤0.01% 2624
2025
Q3 		$826 Buy
+95
New +$568 ﹤0.01% 2573
2025
Q1 		– Sell
-463
Closed -$2.58K – 2775
2024
Q4 		$2.58K Buy
+463
New +$3.63K ﹤0.01% 2463

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Quadrant Capital Group's FDMT Position: Q2 2026 in Review

Quadrant Capital Group sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 95 shares — an estimated $885 sold.

Quadrant Capital Group first reported a position in FDMT in Q4 2024 and held it in 4 quarters. The position peaked at $2.58K in Q4 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Quadrant Capital Group reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 95 4D Molecular Therapeutics shares in Q2 2026, an estimated $885.
  • Quadrant Capital Group first reported a position in 4D Molecular Therapeutics in Q4 2024 and held it in 4 quarters.
  • Quadrant Capital Group's 4D Molecular Therapeutics position peaked at $2.58K in Q4 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.